inflammatory bowel disease

Efficacy and Implementation of a Digital Cognitive Behavioural Self-Management Programme (IBD-BOOST) for Fatigue, Pain, and Faecal Incontinence in Inflammatory Bowel Disease: A Comprehensive Review

By MedXY 11/23/2025

This review evaluates the IBD-BOOST digital cognitive behavioural self-management intervention's design, trial outcomes, process evaluation, and clinical implications for managing fatigue, pain, and faecal incontinence in IBD.

Dermatology Gastroenterology

IL23R Polymorphism as a Genetic Predictor of Paradoxical Psoriasis in Anti-TNFα-Treated IBD Patients

By MedXY 10/09/2025

The IL23R1142G>A genetic variant strongly predicts paradoxical psoriasis in inflammatory bowel disease patients undergoing anti-TNFα therapy, guiding personalized treatment decisions.

Gastroenterology news

Gut Microbiota as a Key Determinant of Quality of Life Impairment in Inflammatory Bowel Disease

By MedXY 10/09/2025

A recent cross-sectional study reveals that alterations in gut microbiota correlate more strongly with impaired health-related quality of life in IBD patients than clinical disease activity, suggesting novel microbial therapeutic targets beyond immunosuppression.

Gastroenterology news Specialties

Unraveling the Paradox: Why Smoking Benefits Ulcerative Colitis but Worsens Crohn’s Disease

By MedXY 09/04/2025

Recent research elucidates how smoking modulates gut microbiota and immune responses differently in ulcerative colitis and Crohn’s disease, explaining its protective effect in UC but detrimental role in CD.

Family Medicine & Nutrition Gastroenterology news Specialties

Unmasking Fructose: How a Common Sweetener Sparks Immune Attacks and Inflammatory Bowel Disease—And How Metformin Offers Hope

By MedXY 08/26/2025

High fructose intake can directly activate immune cells, worsening intestinal inflammation linked to IBD, but the diabetes drug metformin shows promise in reversing these effects.

Clinical Updates Gastroenterology Specialties

Afimkibart, an Anti-TL1A Antibody, in Moderately-to-Severely Active Ulcerative Colitis: Insights from the Phase 2b TUSCANY-2 Trial

By MedXY 08/26/2025

The TUSCANY-2 phase 2b trial evaluated afimkibart, a novel anti-TL1A antibody, in moderately-to-severely active ulcerative colitis, demonstrating favorable safety and clinically meaningful remission rates using modified Mayo scores despite primary endpoint statistical thresholds not being met by total Mayo scores.